Z Vegh1, J Burisch2, N Pedersen3, I Kaimakliotis4, D Duricova5, M Bortlik5, K Kofod Vinding6, S Avnstrøm7, J Olsen8, K R Nielsen8, K H Katsanos9, E V Tsianos9, L Lakatos10, D Schwartz11, S Odes12, R D'Incà13, M Beltrami14, G Kiudelis15, L Kupcinskap15, A Jucov16, S Turcan16, L F Barros17, F Magro18, D Lazar19, A Goldis19, L de Castro20, V Hernandez20, O Niewiadomski21, S Bell21, E Langholz22, P Munkholm23, P L Lakatos11. 1. First Department of Medicine, Semmelweis University, Budapest, Hungary veghzsuzsi@gmail.com. 2. Gastrounit, Medical Section, Hvidovre University Hospital, Hvidovre, Denmark. 3. Gastroenterology Department, Slagelse University Hospital, Slagelse, Denmark. 4. Nicosia private practice, Cyprus. 5. IBD Centre ISCARE, Charles University, Prague, Czech Republic. 6. Digestive Disease Centre, Medical Section, Herlev University Hospital, Copenhagen, Denmark. 7. Department of Medicine, Amager Hospital, Amager, Denmark. 8. Medical Department, National Hospital of the Faroe Islands, Torshavn, Faroe Islands. 9. First Division of Internal Medicine and Division of Gastroenterology, Faculty of Medicine, University of Ioannina, Ioannina, Greece. 10. Department of Medicine, Csolnoky F. Province Hospital, Veszprem, Hungary. 11. First Department of Medicine, Semmelweis University, Budapest, Hungary. 12. Department of Gastroenterology and Hepatology, Soroka Medical Centre and Ben-Gurion University of the Negev, Beer Sheva, Israel. 13. UO Gastroenterologia, Azienda Ospedaliera-Università di Padova, Padova, Italy On behalf of the EpiCom Northern Italy centre based in Crema, Cremona, Firenze, Forlì & Padova and Reggio Emilia, Italy. 14. Degenza Breve Internistica e Centro M.I.C.I.-Azienda Ospedaliera Arcispedale S Maria Nuova, Reggio Emilia, Italy On behalf of the EpiCom Northern Italy centre based in Crema, Cremona, Firenze, Forlì & Padova and Reggio Emilia, Italy. 15. Institute for Digestive Research, Lithuanian University of Health Sciences, Kaunas, Lithuania. 16. Department of Gastroenterology, State University of Medicine and Pharmacy, Chisinau, Republic of Moldova. 17. Hospital de Vale de Sousa, Porto, Portugal. 18. Department of Gastroenterology, Hospital de São João, Porto, Portugal Department of Pharmacology and Therapeutics, Oporto Medical School, Porto, Portugal MedInUP-Centre for Drug Discovery and Innovative Medicines, University of Porto, Porto, Portugal. 19. Clinic of Gastroenterology, University of Medicine 'Victor Babes', Timisoara, Romania. 20. Department of Gastroenterology, Grupo de Investigación en Patología Digestiva, Instituto de Investigación Biomedica [IBI], Xerencia de Xestión Integrada de Vigo, SERGAS, Vigo, Spain. 21. Department of Gastroenterology, St Vincent's Hospital, Melbourne, Victoria, Australia. 22. Department C, Gastroenterology Section, Herlev and Gentofte Hospital, Hellerup, Denmark. 23. Gastro Unit, Medical Section, North Zealand Hospital, University of Copenhagen, Denmark.
Abstract
BACKGROUND AND AIMS: The ECCO-EpiCom study investigates the differences in the incidence and therapeutic management of inflammatory bowel diseases [IBD] between Eastern and Western Europe. The aim of this study was to analyse the differences in the disease phenotype, medical therapy, surgery, and hospitalization rates in the ECCO-EpiCom 2011 inception cohort during the first year after diagnosis. METHODS: Nine Western, five Eastern European centres and one Australian centre with 258 Crohn's disease [CD], 380 ulcerative colitis [UC] and 71 IBD unclassified [IBDU] patients [female/male: 326/383; mean age at diagnosis: 40.9 years, SD: 17.3 years] participated. Patients' data were registered and entered in the web-based ECCO-EpiCom database [www.epicom-ecco.eu]. RESULTS: In CD, 36 [19%] Western Europe/Australian and 6 [9%] Eastern European patients received biological therapy [p = 0.04], but the immunosuppressive [IS] use was equal and high in these regions [Eastern Europe vs Western Europe/Australia: 53% vs 45%; p = 0.27]. Surgery was performed in 17 [24%] CD patients in Eastern Europe and 13 [7%] in Western Europe/Australia [p < 0.001, pLogRank = 0.001]. Of CD patients from Eastern Europe, 24 [34%] were hospitalized, and 39 [21%] from Western Europe/Australia, [p = 0.02, pLogRank = 0.01]. In UC, exposure to biologicals and colectomy rates were low and hospitalization rates did not differ between these regions during the 1-year follow-up period [16% vs 16%; p = 0.93]. CONCLUSIONS: During the first year after diagnosis, surgery and hospitalization rates were significantly higher in CD patients in Eastern Europe compared with Western Europe/Australia, whereas significantly more CD patients were treated with biologicals in the Western Europe/Australian centres.
BACKGROUND AND AIMS: The ECCO-EpiCom study investigates the differences in the incidence and therapeutic management of inflammatory bowel diseases [IBD] between Eastern and Western Europe. The aim of this study was to analyse the differences in the disease phenotype, medical therapy, surgery, and hospitalization rates in the ECCO-EpiCom 2011 inception cohort during the first year after diagnosis. METHODS: Nine Western, five Eastern European centres and one Australian centre with 258 Crohn's disease [CD], 380 ulcerative colitis [UC] and 71 IBD unclassified [IBDU] patients [female/male: 326/383; mean age at diagnosis: 40.9 years, SD: 17.3 years] participated. Patients' data were registered and entered in the web-based ECCO-EpiCom database [www.epicom-ecco.eu]. RESULTS: In CD, 36 [19%] Western Europe/Australian and 6 [9%] Eastern European patients received biological therapy [p = 0.04], but the immunosuppressive [IS] use was equal and high in these regions [Eastern Europe vs Western Europe/Australia: 53% vs 45%; p = 0.27]. Surgery was performed in 17 [24%] CDpatients in Eastern Europe and 13 [7%] in Western Europe/Australia [p < 0.001, pLogRank = 0.001]. Of CDpatients from Eastern Europe, 24 [34%] were hospitalized, and 39 [21%] from Western Europe/Australia, [p = 0.02, pLogRank = 0.01]. In UC, exposure to biologicals and colectomy rates were low and hospitalization rates did not differ between these regions during the 1-year follow-up period [16% vs 16%; p = 0.93]. CONCLUSIONS: During the first year after diagnosis, surgery and hospitalization rates were significantly higher in CDpatients in Eastern Europe compared with Western Europe/Australia, whereas significantly more CDpatients were treated with biologicals in the Western Europe/Australian centres.
Authors: Steven F G Jeuring; Tim R A van den Heuvel; Limmie Y L Liu; Maurice P Zeegers; Wim H Hameeteman; Mariëlle J L Romberg-Camps; Liekele E Oostenbrug; Ad A M Masclee; Daisy M A E Jonkers; Marieke J Pierik Journal: Am J Gastroenterol Date: 2016-12-06 Impact factor: 10.864
Authors: María Chaparro; Manuel Barreiro-de Acosta; José Manuel Benítez; José Luis Cabriada; María José Casanova; Daniel Ceballos; María Esteve; Hipólito Fernández; Daniel Ginard; Fernando Gomollón; Rufo Lorente; Pilar Nos; Sabino Riestra; Montserrat Rivero; Pilar Robledo; Cristina Rodríguez; Beatriz Sicilia; Emilio Torrella; Ana Garre; Esther García-Esquinas; Fernando Rodríguez-Artalejo; Javier P Gisbert Journal: Therap Adv Gastroenterol Date: 2019-05-21 Impact factor: 4.409
Authors: Zsuzsanna Kurti; Akos Ilias; Lorant Gonczi; Zsuzsanna Vegh; Petra Fadgyas-Freyler; Gyula Korponay; Petra A Golovics; Barbara D Lovasz; Peter L Lakatos Journal: BMC Gastroenterol Date: 2018-01-30 Impact factor: 3.067
Authors: Min Seob Kwak; Jae Myung Cha; Ji Hyun Ahn; Min Kyu Chae; Sara Jeong; Hun Hee Lee Journal: Medicine (Baltimore) Date: 2020-03 Impact factor: 1.889